Form 4: Director Sells UTHR Shares Under 10b5-1 Plan
Insider Transaction Report
United Therapeutics Director Jan Malcolm sold 45 shares of common stock for $533.51 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Director Jan Malcolm of United Therapeutics Corp (UTHR) reported a sale of common stock.
- The transaction involved the disposition of 45 shares of UTHR common stock.
- The shares were sold at a price of $533.51 per share.
- This sale was executed on March 17, 2026.
- Following this transaction, Jan Malcolm directly beneficially owns 125 shares of UTHR common stock.
- The sale was conducted pursuant to a Rule 10b5-1 trading plan established on September 11, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. While an insider sale can sometimes be perceived negatively, the execution under a pre-established 10b5-1 plan mitigates concerns about opportunistic selling based on new, non-public information.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that insider sales, even under 10b5-1 plans, are routinely monitored by investors for potential signals regarding management's view of future stock performance. While a 10b5-1 plan suggests the sale is not based on new, non-public information, the timing and volume can still be of interest.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Policy Adherence | Director Jan Malcolm executed a sale of common stock under a Rule 10b5-1 trading plan, which was established on September 11, 2025. This plan allows insiders to set up a pre-arranged schedule for buying or selling company stock to avoid accusations of trading on material non-public information. | 09/11/2025 | Enhances transparency and reduces the perception of opportunistic insider trading, aligning with best practices for corporate governance regarding executive stock transactions. |
Stakeholder Impact
- Shareholders: May observe the director's sale, but the 10b5-1 plan context suggests it's a routine, pre-planned event rather than a signal of negative sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/11/2025 | Date Rule 10b5-1 trading plan was entered into by Jan Malcolm. |
| 03/17/2026 | Date of common stock transaction by Jan Malcolm. |
Recommendation
holdThe sale of 45 shares by Director Jan Malcolm, executed under a pre-established Rule 10b5-1 trading plan, is a routine insider transaction. It does not provide new material information about the company's operational performance or strategic direction that would necessitate a change from a 'hold' recommendation. Investors should continue to evaluate United Therapeutics based on its fundamental business performance and broader market conditions.
Keywords
United Therapeutics, UTHR, Insider Trading, Form 4, Director Sale, 10b5-1 Plan, Stock Transaction, Jan Malcolm
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.